Medicinal Cannabis for Gastrointestinal Disorders: Evidence and Recommendations

Join Dr Scott Smid, Senior Lecturer at the University of Adelaide, as we delve into the therapeutic potential of medicinal cannabis in gastrointestinal disorders.

About the Webinar

Join Dr. Scott Smid, Senior Lecturer at the University of Adelaide, as we delve into the therapeutic potential of medicinal cannabis and cannabinoids in gastrointestinal disorders. From the complexities of Crohn's disease or intestinal mucositis to the challenges of managing IBS, these conditions underscore the urgent need for effective treatments. Explore the intricate mechanisms by which cannabinoids can influence inflammation, gut motility, and symptom alleviation, offering promising avenues for improved patient outcomes. Gain practical insights into optimal dosing regimens, diverse administration methods, and the importance of patient education in navigating cannabinoid therapy. Furthermore, we'll dissect the latest research findings, unveiling the evolving landscape of medicinal cannabis for gastrointestinal disorders and its implications for future treatment strategies.

Learning Outcomes

Understand how cannabinoids impact inflammation, gut motility, and symptom management in gastrointestinal disorders, leading to potential improvements in patient outcomes
Apply practical insights on dosing, administration methods, and patient education to optimize cannabinoid therapy for gastrointestinal disorders.
Analyse the latest research findings on medicinal cannabis in gastrointestinal disorders to inform future therapeutic approaches in gastroenterology.

About the speaker

Dr Scott Smid is a pharmacologist specializing in drug discovery and development research both in industry and academia. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for gastrointestinal and neurodegenerative diseases. This includes investigating the biological actions of phytocannabinoids, synthetic cannabinoids and endocannabinoids in areas as diverse as gut function, inflammation and neurodegeneration. Current interests include novel ligand development for binding and inhibiting pathological aggregating proteins such as beta-amyloid and alpha-synuclein, which are associated with Alzheimer's and Parkinson's disease.


When: Tuesday, 14 May 2024

Time: 7:00 pm

Cost: Free

By registering for this webinar, you consent to receiving communications from Medihuanna and our sponsors related to this event.

Claim 1 CPD Hour

Medihuanna is a CPD approved education provider, and this activity has been approved by the RACGP (Activity ID: 848768). Upon completing this activity, you will be eligible to claim CPD hours. The activity will include the following CPD allocation which will be uploaded to the RACGP dashboard.